These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16270834)

  • 21. Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease.
    To N; Gracie DJ; Ford AC
    Aliment Pharmacol Ther; 2016 Feb; 43(3):440. PubMed ID: 26782114
    [No Abstract]   [Full Text] [Related]  

  • 22. [Inflammation activity and loss of plasma proteins in nonspecific inflammatory diseases of the large intestine].
    Rumiantsev VG; Kabanova IN; Kirkin BV; Minaeva OD
    Sov Med; 1988; (4):15-7. PubMed ID: 3406814
    [No Abstract]   [Full Text] [Related]  

  • 23. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn's disease.
    Coruzzi P; Castiglioni P; Parati G; Brambilla V; Brambilla L; Gualerzi M; Cademartiri F; Franzè A; De Angelis G; Di Rienzo M; Di Mario F
    Eur J Clin Invest; 2007 Dec; 37(12):964-70. PubMed ID: 18036030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets.
    Kraneveld AD; Rijnierse A; Nijkamp FP; Garssen J
    Eur J Pharmacol; 2008 May; 585(2-3):361-74. PubMed ID: 18417115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proceedings: Complement in inflammatory bowel disease.
    Hodgson HJ; Potter BJ; Jewell DP
    Gut; 1975 Oct; 16(10):833-4. PubMed ID: 1205305
    [No Abstract]   [Full Text] [Related]  

  • 26. Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply.
    De Bie C; Ferrante M
    Aliment Pharmacol Ther; 2016 Feb; 43(3):441. PubMed ID: 26782115
    [No Abstract]   [Full Text] [Related]  

  • 27. Transcobalamin and inflammatory bowel disease.
    Carmel R
    Gastroenterology; 1980 Jun; 78(6):1660-1. PubMed ID: 7372088
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacokinetics of Azulfidine/Salazopyrin in healthy humans and in patients with chronic inflammatory bowel diseases].
    Van Hees PA
    Z Gastroenterol Verh; 1981 Jun; 19():7-14. PubMed ID: 6168136
    [No Abstract]   [Full Text] [Related]  

  • 29. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I; Hasan F; Khan I
    Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inflammatory bowel disease: experience of two Chilean centers].
    Figueroa C C; Quera P R; Valenzuela E J; Jensen B C
    Rev Med Chil; 2005 Nov; 133(11):1295-304. PubMed ID: 16446852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
    Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
    Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
    Desreumaux P; Ghosh S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How Toll-like receptors signal: what we know and what we don't know.
    O'Neill LA
    Curr Opin Immunol; 2006 Feb; 18(1):3-9. PubMed ID: 16343886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPARgamma as a new therapeutic target in inflammatory bowel diseases.
    Dubuquoy L; Rousseaux C; Thuru X; Peyrin-Biroulet L; Romano O; Chavatte P; Chamaillard M; Desreumaux P
    Gut; 2006 Sep; 55(9):1341-9. PubMed ID: 16905700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of sleep disturbances in inflammatory bowel disease.
    Ranjbaran Z; Keefer L; Farhadi A; Stepanski E; Sedghi S; Keshavarzian A
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1748-53. PubMed ID: 17914945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pathological aspects of inflammatory bowel disease.
    Marteau P
    Nestle Nutr Workshop Ser Clin Perform Programme; 1999; 2():83-92. PubMed ID: 11490630
    [No Abstract]   [Full Text] [Related]  

  • 37. Determinants of bone density in inflammatory bowel disease.
    Bernstein CN
    Gastroenterology; 1995 May; 108(5):1607-9. PubMed ID: 7729662
    [No Abstract]   [Full Text] [Related]  

  • 38. Complement and function of neutrophils in chronic inflammatory bowel disease.
    Elmgreen J
    Dan Med Bull; 1986 Oct; 33(5):222-8. PubMed ID: 3536336
    [No Abstract]   [Full Text] [Related]  

  • 39. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
    Prantera C; Scribano ML
    Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.